Medical Treatment
Study finds lecanemab clears amyloid but shows no short-term recovery in brain waste-clearance system
Iniulat ng AI Larawang ginawa ng AI Fact checked
Researchers at Osaka Metropolitan University report that while the Alzheimer’s drug lecanemab reduces amyloid plaques, MRI measures found no improvement in the brain’s glymphatic waste-clearance three months after treatment began, underscoring the disease’s complexity and the need for multi-target approaches.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Iniulat ng AI
Judy Wanyoike was diagnosed with stage 2B cervical cancer in 2012 following a Pap Smear test. Despite surgery, chemotherapy, and radiation therapy, the cancer returned in 2019 and again in 2022. Experts stress the need for early detection to prevent recurrence.